Patrys Ltd
ASX:PAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Patrys Ltd
Operating Expenses
Patrys Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Patrys Ltd
ASX:PAB
|
Operating Expenses
-AU$4.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
6%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Expenses
-$111.3m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
CSL Ltd
ASX:CSL
|
Operating Expenses
-$4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-11%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Operating Expenses
-AU$11.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Expenses
-AU$350.9m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Expenses
-AU$71m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-30%
|
|
Patrys Ltd
Glance View
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
See Also
What is Patrys Ltd's Operating Expenses?
Operating Expenses
-4.6m
AUD
Based on the financial report for Dec 31, 2025, Patrys Ltd's Operating Expenses amounts to -4.6m AUD.
What is Patrys Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
6%
Over the last year, the Operating Expenses growth was -1%. The average annual Operating Expenses growth rates for Patrys Ltd have been 22% over the past three years , -3% over the past five years , and 6% over the past ten years .
